Preview

Научно-практическая ревматология

Расширенный поиск

Новые возможности контроля эффективности метотрексата при ревматоидном артрите

https://doi.org/10.14412/1995-4484-2015-308-311

Полный текст:

Аннотация

Обзор посвящен прогнозированию лечебного эффекта метотрексата при ревматоидном артрите с помощью определения его уровня в эритроцитах

Об авторе

Ю. В. Муравьев
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А
Россия


Список литературы

1. Насонов ЕЛ. Метотрексат: перспективы применения в ревматологии. Москва: Филоматис; 2005. 200 с. [Nasonov EL. Metotreksat: perspektivy primeneniya v evmatologii [Methotrexate: prospects of application in rheumatology]. Moscow: Filomatis; 2005. 200 p.].

2. Kay J, Westhovens R. Methotrexate: the gold standard without standardization. Ann Rheum Dis. 2009;68:1081–2. doi: 10.1136/ard.2008.102822

3. Pincus T, Yazici Y, Sokka T, et al. Methotrexate as the «anchor drug» for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21:179–85.

4. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159:2542–50. doi: 10.1001/archinte.159.21.2542

5. Wessels JA, van der Kooij SM, le Cessie S, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 2007;56:1765–75. doi: 10.1002/art.22640

6. Муравьев ЮВ. Вопросы стандартизации применения метотрексата в ежедневной практике ревматолога (обзор). Терапевтический архив. 2011;(5):33–7 [Murav'ev YuV. Questions of standardization of methotrexate in the daily practice of a rheumatologist (a review). Terapevticheskii arkhiv. 2011;(5):33–7 (In Russ.)].

7. Муравьев ЮВ, Евлоева НВ, Лебедева ВВ, Насонов ЕЛ. Современная практика лечения метотрексатом ревматоидного артрита. Научно-практическая ревматология. 2012;50(4):117–9 [Murav'ev YuV, Evloeva NV, Lebedeva VV, Nasonov EL. The modern practice of methotrexate treatment of rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;50(4):117–9 (In Russ.)].

8. Муравьев ЮВ. Дозирование метотрексата при лечении ревматоидного артрита. Научно-практическая ревматология. 2013;51(4):456–9 [Murav'ev YuV. Dosage of methotrexate in the treatment of rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(4):456–9 (In Russ.)].

9. Furst DE, Koehnke R, Burmeister LF, et al. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol. 1989;16(3):313-20.

10. Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996;30:194–210. doi: 10.2165/00003088-199630030-00002

11. Baggott JE, Morgan SL. Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation. Arthritis Rheum. 2009 Aug;60(8):2257–61. doi: 10.1002/art.24685

12. Dervieux T, Furst D, Lein DO, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004;50:2766–74. doi: 10.1002/art.20460

13. Dervieux T, Zablocki R, Kremer J. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology. 2010;49:2337–45. doi: 10.1093/rheumatology/keq216

14. Angelis-Stoforidis P, Vajda FJ, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol. 1999;17:313–20.

15. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 1986;29:822–31. doi: 10.1002/art.1780290702

16. Hroch M, Tukova J, Dolezalova P, Chladek J. An improved high-performance liquid chromatography method for quantification of methotrexate polyglutamates in red blood cells of children with juvenile idiopathic arthritis. Biopharm Drug Dispos. 2009;30:138–48. doi: 10.1002/bdd.654

17. Becker ML, Gaedigk R, van Haandel L, et al. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum. 2011;63:276–85. doi: 10.1002/art.30080

18. Becker ML, van Haandel L, Gaedigk R, et al. Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations. Arthritis Rheum. 2010;62:1803–12. doi: 10.1002/art.27434

19. Goldman ID. The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann N Y Acad Sci. 1971;186:400–22. doi: 10.1111/j.1749-6632.1971.tb46996.x

20. Westerhof GR, Schornagel JH, Kathmann I, et al. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes:correlates of molecular structure and biological activity. Mol Pharmacol. 1995;48:459–71.

21. Jansen G, Mauritz R, Drori S, et al. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem. 1998;273:189–98. doi: 10.1074/jbc.273.46.30189

22. Jansen G, Pieters R. The role of impaired transport in (pre)clinical resistance to methotrexate: insights on new antifolates. Drug Resist Updat. 1998;1(3):211–8. doi: 10.1016/S1368-7646(98)80042-3

23. Rots MG, Pieters R, Kaspers GJ, et al. Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia. Br Haematol. 2000;110:791–800. doi: 10.1046/j.1365-2141.2000.02070.x

24. Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985;76(3):907–12. Review. doi: 10.1172/JCI112088

25. Kremer JM. Still trying to understand methotrexate. J Rheumatol. 2014;41(11):2099–101. doi: 10.3899/jrheum.141081

26. Dalrymple JM, Stamp LK, O'Donnell JL, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58:3299–308. doi: 10.1002/art.24034

27. Weinblatt ME, Trentham DE, Fraser PA, et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum. 1988;31:167–75. doi: 10.1002/art.1780310203

28. Dervieux T, Furst D, Lein DO, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis. 2005;64:1180–5. doi: 10.1136/ard.2004.033399

29. Cronstein BN. Going with flow: methotrexate, adenosine, and blood flow. Ann Rheum Dis. 2006;65:421–2. doi: 10.1136/ard.2005.049601

30. Riksen NP, Barrera P, van den Broek PH, et al. Methotrexat modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis. 2006;65:466–70. doi: 10.1136/ard.2005.048637

31. Dervieux T, Greenstein N, Kremer J. Pharmacogenetic andmetabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 2006;54:3095–103. doi: 10.1002/art.22129

32. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by olyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole- 4-carboxamide riboside and ribotide. Biochem J. 1986;236(1):193–200.

33. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosyl aminoimidazole carboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA. 1985;82(15):4881–5. doi: 10.1073/pnas.82.15.4881

34. Stamp LK, O'Donnell JL, Chapman PT, et al. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patientsreceiving long-term methotrexate treatment. Arthritis Rheum. 2009;60:2248–56. doi: 10.1002/art.24653

35. Hobl EL, Jilma B, Erlacher L, et al. A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate. Clin Exp Rheumatol. 2011 Dec 7. [Epub ahead of print].

36. Kremer JM, Rynes RI, Bartholomew LE. Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind study. Am J Med. 1987;82(4):781–6. doi: 10.1016/0002-9343(87)90015-5

37. Stamp LK, O'Donnell JL, Chapman PT, et al. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum. 2009;60(8):2248–56. doi: 10.1002/art.24653

38. Stamp LK, Barclay ML, O'Donnell JL, et al. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol. 2011;38(12):2540–7. doi: 10.3899/jrheum.110481

39. Stamp LK, Barclay M. Therapeutic drug monitoring in rheumatic diseases: utile or futile? Rheumatology (Oxford). 2014;53(6):988–97. doi: 10.1093/rheumatology/ket355

40. Pan S, Stamp LK, Duffull SB, et al. Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis. Clin Pharmacokinet. 2014;53(12):1161–70. doi: 10.1007/s40262-014-0179-5


Для цитирования:


Муравьев Ю.В. Новые возможности контроля эффективности метотрексата при ревматоидном артрите. Научно-практическая ревматология. 2015;53(3):308-311. https://doi.org/10.14412/1995-4484-2015-308-311

For citation:


Muravyev Y.V. NEW POSSIBILITIES FOR MONITORING METHOTREXATE EFFICACY IN RHEUMATOID ARTHRITIS. Rheumatology Science and Practice. 2015;53(3):308-311. (In Russ.) https://doi.org/10.14412/1995-4484-2015-308-311

Просмотров: 498


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)